Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Neuropathic Pain Therapeutics market. The report identifies the key trends shaping and driving the global Neuropathic Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Neuropathic Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Neuropathic Pain Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Neuropathic Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Neuropathic Pain Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Neuropathic Pain Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Neuropathic Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Neuropathic Pain Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Neuropathic Pain Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Neuropathic Pain Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Neuropathic Pain Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Chronic Pain is Further Divided Into
2.2 Etiology and Pathophysiology
2.3 Signs and Symptoms
2.4 Epidemiology
2.5 Diagnosis
2.5.1 McGill Pain Questionnaire (MPQ)
2.5.2 Neuropathic Pain Scale (NPS)
2.5.3 Quantitative Sensory Testing (QST)
2.6 Treatment and Management Pattern
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance

3 Neuropathic Pain Therapeutics - Market Characterization
3.1 Neuropathic Pain Therapeutics Market Size (2005-2010) - Global
3.2 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - Global
3.3 Neuropathic Pain Therapeutics Market Size (2005-2010) - The US
3.4 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - The US
3.5 Neuropathic Pain Therapeutics Market Size (2005-2010) - The UK
3.6 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - The UK
3.7 Neuropathic Pain Therapeutics Market Size (2005-2010) - France
3.8 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - France
3.9 Neuropathic Pain Therapeutics Market Size (2005-2010) - Germany
3.10 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - Germany
3.11 Neuropathic Pain Therapeutics Market Size (2005-2010) - Italy
3.12 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - Italy
3.13 Neuropathic Pain Therapeutics Market Size (2005-2010) - Spain
3.14 Neuropathic Pain Therapeutics Market Forecast (2010-2018) - Spain
3.15 Neuropathic Pain Therapeutics Market Size (2005-2010) - Japan
3.16 Neuropathic Pain Therapeutics Market Size (2010-2018) - Japan
3.17 Drivers and Barriers for the Neuropathic Pain Therapeutics Market
3.17.1 Drivers for Neuropathic Pain Market
3.17.2 Barriers for Neuropathic Pain Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 Neuropathic Pain Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Neuropathic Pain Therapeutics Market
4.3.1 Lyrica (pregabalin)
4.3.2 Cymbalta (duloxetine)
4.3.3 Lidoderm (lidocaine patch 5%)
4.3.4 Neurontin (gabapentin)
4.3.5 Qutenza (capsaicin) 8% Patch
4.4 Key Takeaway

5 Global Neuropathic Pain Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Neuropathic Pain Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Neuropathic Pain Therapeutics - Regulatory Filed Products
5.3.2 Neuropathic Pain Therapeutics - Phase III Pipeline
5.3.3 Neuropathic Pain Therapeutics - Phase II Pipeline
5.3.4 Neuropathic Pain Therapeutics - Phase I Pipeline
5.3.5 Neuropathic Pain Market - Discovery and Pre-Clinical Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 Neuropathic Pain Therapeutics Market - Pipeline by Mechanism of Action
5.5 Neuropathic Pain Therapeutics - Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 AVP-923 (Zenvia)
5.6.2 Fentora (fentanyl buccal tablet)
5.6.3 Nucynta ER (tapentadol)
5.6.4 AS-3201 (ranirestat)
5.7 Key Takeaway

6 Neuropathic Pain Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Sponsors
6.5 Top Companies Participating in Neuropathic Pain Therapeutics Clinical Trials

7 Neuropathic Pain Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Neuropathic Pain Therapeutics: Implications for Future Market Competition

8 Neuropathic Pain Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Pfizer Inc.
8.2.2 Grunenthal GmbH
8.2.3 Avanir Pharmaceuticals
8.2.4 Cephalon Inc.
8.2.5 Endo Pharmaceuticals
8.2.6 Dainippon Sumitomo Pharma Co., Ltd.
8.2.7 NeurogesX Inc.
8.2.8 Other Companies in the Neuropathic Pain Therapeutics Market

9 Neuropathic Pain Therapeutics - Licensing and Partnership Deals

10 Neuropathic Pain Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables

Table 1: Differentiation of Chronic Pain from Acute Pain
Table 2: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005-2010
Table 3: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010-2018
Table 4: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005-2010
Table 5: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010-2018
Table 6: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 7: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 8: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010-2018
Table 10: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 12: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 14: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 16: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 17: Neuropathic Pain Therapeutics Market, Japan, Forecast ($bn), 2010-2018
Table 18: Neuropathic Pain Therapeutics, Regulatory Filed Products, 2011
Table 19: Neuropathic Pain Therapeutics, Phase III Pipeline, 2011
Table 20: Neuropathic Pain Therapeutics, Phase II Pipeline, 2011
Table 21: Neuropathic Pain Therapeutics, Phase I Pipeline, 2011
Table 22: Neuropathic Pain Therapeutics, Discovery and Pre-Clinical Pipeline, 2011
Table 23: Neuropathic Pain Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 24: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011
Table 25: Neuropathic Pain Therapeutics - Clinical Trials by Phase, 2011
Table 26: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011
Table 27: Neuropathic Pain Therapeutics, Prominent Sponsors, 2011
Table 28: Neuropathic Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Pfizer Inc., Pain Management, Pipeline, 2011
Table 30: Pfizer, Inc., Deals, 2010-2011
Table 31: Grunenthal GmbH, Pain Management, Pipeline, 2011
Table 32: Grunenthal GmbH, Deals, 2010-2011
Table 33: Avanir Pharmaceuticals - Pain Management, Pipeline, 2011
Table 34: Avanir Pharmaceuticals - Deals, 2009-2011
Table 35: Cephalon, Inc., Pain Management Pipeline, 2011
Table 36: Cephalon Inc., Deals, 2010-2011
Table 37: Endo Pharmaceuticals, Pain Management, Pipeline, 2011
Table 38: Endo Pharmaceuticals, Deals, 2011
Table 39: Dainippon Sumitomo Pharma Co., Ltd, Pain Management, Pipeline, 2011
Table 40: Dainippon Sumitomo Pharma Co., Ltd., Deals, 2011
Table 41: NeurogesX, Inc., Pain Management, Pipeline, 2011
Table 42: NeurogesX Inc., Deals, 2011
Table 43: Neuropathic Pain Therapeutics Market, Future Players
Table 44: Neuropathic Pain Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures

Figure 1: Classification of Chronic Pain and Representative Indications
Figure 2: Development of Neuropathic Pain
Figure 3: Etiology of Neuropathic Pain
Figure 4: Pathophysiological Mechanisms of Neuropathic Pain
Figure 5: Pathophysiology of Neuropathic Pain
Figure 6: Sign s and Symptoms of Neuropathic Pain
Figure 7: Signs and Symptoms of Neuropathic Pain
Figure 8: Pain Measurement Scale - Faces Rating Scale
Figure 9: Treatment Approach in Neuropathic Pain
Figure 10: Neuropathic Pain Treatment Pathway
Figure 11: Referral Pathway for Neuropathic Pain
Figure 12: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005-2010
Figure 13: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010-2018
Figure 14: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005-2010
Figure 15: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010-2018
Figure 16: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 17: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 18: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 19: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 20: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 21: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 22: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 23: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 24: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 25: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 26: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 27: Neuropathic Pain Therapeutics Market, Japan, Revenue ($bn), 2010-2018
Figure 28: Opportunity and Unmet Need (Oral Drugs) in the Neuropathic Pain Therapeutics Market, 2010
Figure 29: Opportunity and Unmet Need (Topical Patches) in the Neuropathic Pain Therapeutics Market, 2010
Figure 30: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2010
Figure 31: Neuropathic Pain Therapeutics - Pipeline by Phase of Development, 2011
Figure 32: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, 2011
Figure 33: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 34: Neuropathic Pain Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 35: Fentora (fentanyl buccal tablet): Chemical Structure
Figure 36: Nucynta ER (tapentadol): Chemical Structure
Figure 37: AS-3201 (ranirestat): Chemical Structure
Figure 38: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011
Figure 39: Neuropathic Pain Therapeutics, Clinical Trials by Phase (%), 2011
Figure 40: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011
Figure 41: Neuropathic Pain Therapeutics, Overall Sponsors (%), 2011
Figure 42: Neuropathic Pain Therapeutics, Prominent Sponsors (%), 2011
Figure 43: Neuropathic Pain Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 44: Neuropathic Pain Therapeutics Market, Drivers and Barriers, 2011
Figure 45: Implications for Future Market Competition in the Neuropathic Pain Market, 2011
Figure 46: Neuropathic Pain Therapeutics Market, Pipeline by Company, 2011
Figure 47: GlobalData Market Forecasting Model